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Advanced glycation end-products (AGEs) are produced by non-enzymatic glycation between protein and
reducing sugar such as glucose. Although glyceraldehyde-derived AGEs (Glycer-AGEs), one of the AGEs
subspecies, have been reported to be involved in the pathogenesis of various age-relating diseases such
as diabetes mellitus or arteriosclerosis, little is known about the pathological and physiological mech-
anism of AGEs in vivo. In present study, we produced 4 kinds of polyclonal antibodies against AGEs
subspecies and investigated the localization of AGEs-modiﬁed proteins in rat peripheral tissues, making
use of these antibodies. We found that Glycer-AGEs and methylglyoxal-derived AGEs (MGO-AGEs) were
present in pancreatic islets of healthy rats, distinguished clearly into the pancreatic a and b cells,
respectively. Although streptozotocin-induced diabetic rats suffered from remarkable impairment of
pancreatic islets, the localization and deposit levels of the Glycer- and MGO-AGEs were not altered in the
remaining a and b cells. Remarkably, the MGO-AGEs in pancreatic b cells were localized into the insulin-
secretory granules. These results suggest that the cell-speciﬁc localization of AGEs-modiﬁed proteins are
presence generally in healthy peripheral tissues, involved in physiological intracellular roles, such as a
post-translational modulator contributing to the secretory and/or maturational functions of insulin.
© 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus (DM) induces many complications such as
retinopathy, nephropathy and neuropathy.1,2 These diseases have
been suggested for involvement of advanced glycation end prod-
ucts (AGEs).3e5
AGEs are a heterogeneous, complex group of compounds that
represent the ultimate product of multiple reactions occurring in
several conditions, namely, in the chronic hyperglycemic state of
DM. Non-enzymatic glycation begins with interaction and linked
between the carbonyl group of a reducing sugar and an aminoishibori).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).group of a protein.3,6 The complex become to be early stage prod-
ucts such as a Schiff base and Amadori rearrangement products
(e.g., HbA1c), and the compounds such as carboxymethyllysine
(CML), carboxyethyllysine (CEL), and pentosidine (an AGE with
autoﬂuorescent properties) are formed through oxidation, dehy-
dration and condensation.3,6,7
Recent studies have suggested that AGEs were produced not only
from reducing sugars, but also from carbonyl compounds derived
from the autoxidation of sugars and other metabolic pathways.8,9
Five immunochemically distinct classes of AGEs (glucose-derived
AGEs: Glc-AGEs, glyceraldehyde-derived AGEs: Glycer-AGEs, glyco-
laldehyde-derived AGEs; Glycol-AGEs, methylglyoxal-derived AGEs:
MGO-AGEs, and glyoxal-derived AGEs: GO-AGEs) are present in sera
of type 2 diabetic patients on hemodialysis.10 And Glycer-AGEs are
also called toxic AGEs (TAGE), which plays an important role in thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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translational modiﬁcations of AGEs subspecies may accumulate by
aging and be involved in the pathological processes in various dis-
eases, such as DM,3e5 Alzheimer's disease12 and cancer.13 However,
the pathological consequence and physiological functions of AGEs
accumulation are still poorly understood.
In this study, we produced 4 kinds of anti-AGEs subspecies-
speciﬁc rabbit polyclonal antibodies to investigate the distribution
of each AGE in healthy control rats as well as streptozotocin (STZ)-
induced type 1 diabetic rats. The identiﬁcation of AGEs existence in
speciﬁc cells in detail must be the ﬁrst step to understand the
functional roles of them. Altogether, we demonstrate that AGEs are
present in several peripheral tissues in normal rats. In particular,
the Glycer-AGEs and MGO-AGEs were localized in a and b cells in
the pancreatic islets, respectively. Therefore, we speculate that
AGEs may have a speciﬁc role in the secretory processes in
pancreatic islets.
2. Materials and methods
2.1. Experimental animals
All animal experiments were approved by the Institutional Ani-
mal Care and Use Committee of Okayama University, and performed
in accordance with the guidelines of Okayama University on animal
experiments. Adult male animals of Wistar rats and Japanese white
rabbits at 12 weeks age obtained from SLC Japan (Tokyo, Japan). The
experimental type 1 diabetes rats (STZ-induced diabetic rats) were
prepared by intraperitoneal injection of 75 mg/kg streptozotocin
(Wako, Osaka, Japan) dissolved in 0.05 M sodium citrate, pH 4.5.
Healthy control rats were injected with sodium citrate. Forty-eight
hours after streptozotocin injection, diabetic state was conﬁrmed
by the blood glucose levels higher than 300 mg/dL. Rats were
sacriﬁced under anesthesia to obtain the peripheral tissues at 7 days
after the streptozotocin injection. Rabbits were used for the pro-
ductions of anti-AGEs antibodies (See below).
2.2. Synthesis of AGEs
AGEs-modiﬁed bovine serum albumin (BSA) (SigmaeAldrich, St.
Louis, MO, USA) was prepared as described previously.14 BSA was
incubated under sterile conditions with 0.2 M glyceraldehyde
(SigmaeAldrich), glycolaldehyde (SigmaeAldrich), methylglyoxal
(SigmaeAldrich) or glyoxal (Tokyo Chemical Industry, Tokyo, Japan)
in 0.2 M phosphate buffer, pH 7.4, at 37 C for 7 days. Each of AGEs-
BSA was dialyzed at 4 C to remove free aldehyde.
2.3. Production of anti-AGEs-speciﬁc polyclonal antibody
Japanese white rabbits were immunized with AGEs-BSA emulsi-
ﬁed with Freund's complete adjuvant (Wako). The booster injection
with Freund's incomplete adjuvant (Wako) was administered 3
weeks later. After whole blood was collected from the immunized
rabbits under anesthesia, the antisera titers were determined by
immunoblot analysis asmentionedbelow. Immunoglobulin fractions
were precipitated from the sera by ammonium sulfate as described
previously.15 After extensive dialysis, immunoglobulin was puriﬁed
using MEP HyperCel (Pall, Port Washington, NY, USA). Anti-AGEs-
speciﬁc antibodies were puriﬁed by using each of AGEs-BSA immo-
bilized on Sepharose beads (GE Healthcare, Buckinghamshire, UK).
2.4. Enzyme-linked immunosorbent assay (ELISA)
ELISA was performed as previously described.16 ELISA plates
were coated with each of 2 mg/mL AGEs and blocked with 1% skimmilk. Each of rat anti-AGEs-speciﬁc polyclonal antibody was added
to the well of ELISA plates. After overnight incubation at 4 C,
peroxidase-conjugated goat anti-rat IgG (Dako, Glostrup, Denmark)
was added to each well. After 1 h incubation at room temperature,
o-phenylenediamine (Wako) was added to each well. The colori-
metric reactionwas stopped with 3 M sulfuric acid. The absorbance
was measured at 490 nm (Bio-Rad model 450 microplate reader;
Bio-Rad, Hercules, CA, USA).
2.5. Immunohistochemistry
For immunohistochemical staining, parafﬁn-embedded pe-
ripheral tissues were prepared as previously described.17 Each tis-
sue was cut into parafﬁn sections at 5 mm thickness. After
deparafﬁnization, the sections were boiled for the antigen activa-
tion at 120 C for 10 min with 10 mM sodium citrate, pH 6.0.
Subsequently, the sections were incubated with each of 2 mg/mL
anti-AGEs-speciﬁc antibody (anti-Glycer-, anti-Glycol-, anti-MGO-
and anti-GO-AGEs rabbit polyclonal antibodies), 3 mg/mL anti-
insulin mouse monoclonal antibody (Cat. 2IP10 D3E7, HyTest,
Turku, Finland) or 4 mg/mL anti-glucagon mouse monoclonal anti-
body (Cat. ab10988, Abcam, Cambridge, UK). To stain the vesicular
structure, the sections were incubated with 10 mg/mL anti-VAMP2
(vesicle-associated membrane protein 2) mouse or rabbit mono-
clonal antibody (Cat. ab118899, Abcam or Cat. 13508, Cell Signaling,
Danvers, MA, USA). The secondary antibodies used were an Alexa
Fluor 488- or 555-conjugated goat anti-mouse or anti-rabbit IgG
antibody (Invitrogen, Carlsbad, CA, USA). The sections were also
counterstained with 40,6-diamidino-2-phenylindole (DAPI). The
sections were observed under ﬂuorescent confocal microscopy
(Biozero BZ8000; Keyence, Osaka, Japan).
2.6. Immunoblot analysis
Protein samples of AGEs-BSA were prepared for immunoblot
analysis as previously described.18,19 AGEs-BSA was denatured by
boiling at 5 min with Laemmli-modiﬁed buffer [10% sodium
dodecyl sulfate (SDS), 9.3% dithiothreitol (DTT), 30% glycerol,
0.35 M triseCl, pH 6.8]. Each of 1 mg AGEs-BSA sample was loaded
onto 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and
then transferred onto PVDF membranes. The membrane was
blocked with 20% skim milk (wt/vol) and 1% normal goat serum,
and subjected to incubation with 2 mg/mL rabbit polyclonal anti-
body against Glycer-AGEs, Glycol-AGEs, MGO-AGEs or GO-AGEs.
Subsequently, the membranes were incubated with peroxidase-
conjugated goat anti-rabbit IgG (MBL, Nagoya, Japan). The chemi-
luminescent reaction was started by the addition of Luminata Forte
Western HRP Substrate (Millipore, Bedford, MA, USA), and the
chemiluminescence was detected by ImageQuant LAS 4000 mini
(GE Healthcare).
2.7. Statistical analysis
Statistical comparisons were performed using one-way ANOVA
followed by the post hoc Bonferroni test with Ekuseru-Toukei 2010
(Social Survey Research Information, Tokyo, Japan). The mean
values of data are shown alongwith the standard error. P values less
than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Immuno-speciﬁcity of anti-AGEs polyclonal antibodies
Fig. 1AeD shows the speciﬁcity of each polyclonal antibody
against AGEs-BSA adducts using immunoblot analysis. Mobility of
Fig. 1. Speciﬁcity and cross-reactivity of anti-AGEs antibody against each of AGEs-BSA by using immunoblot analysis. The indicated AGEs-modiﬁed BSAs were loaded onto
polyacrylamide gel and subjected to immunoblot analysis with anti-Glycer-AGEs antibody (A), anti-Glycol-AGEs antibody (B), anti-MGO-AGEs antibody (C) or anti-GO-AGEs
antibody (D).
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linked structures between albumin molecules randomly. Anti-
Glycer-AGEs antibody showed cross-reactivity for not only the
Glycer-AGEs but also the MGO-AGEs (Fig. 1A), whereas other anti-
bodies showed the speciﬁc reaction to each of the antigen
(Fig. 1BeD).
Consistent with the results of immunoblot analysis in Fig. 1,
ELISA also showed similar cross-reactivity of antibodies against
each of the AGEs-BSA (Fig. 2).
3.2. Distribution pattern of AGEs in rat peripheral tissues
Positive immunostaining of Glycer-AGEs, which has the most
toxic property among the AGEs subspecies arising in chronic hy-
perglycemia,10 were observed in the brain, pancreas and stomach in
the healthy control rats (Table 1). In peripheral tissues examined in
this study, there seemed to be no difference in the AGEs distribu-
tion between the healthy control rats and the STZ-induced diabetic
rats (Table 1).
To examine the distribution pattern of AGEs subspecies in rat
pancreas, immunohistochemical staining for each of AGEs sub-
species was performed (Fig. 3). We observed that Glycer-AGEs and
MGO-AGEs were located in the pancreatic islets, but Glycol-AGEs
and GO-AGEs were not (Fig. 3A). The staining pattern of anti-
Glycer-AGEs antibody was clearly different from that of anti-
MGO-AGEs antibody (Fig. 3A).
Glycer-AGEs were localized to the periphery of each pancreatic
islet in the healthy control rats, which corresponded to thehistological localization of a cells. In fact, double immunohisto-
chemical staining for Glycer-AGEs and glucagon showed that both
staining merged mostly (arrowheads in Fig. 3B). However, some
glucagon-negative cells in the periphery of islets were positive for
Glycer-AGEs (arrow in Fig. 3B). These Glycer-AGEs-positive cells are
most likely the d cells or PP cells judging from the histological
feature. Double immunohistochemical staining for Glycer-AGEs
and insulin did not show the co-localization of both antigens in
the pancreatic islets (Fig. 3C).
On the other hand, immuno-reactivities of MGO-AGEs were
merged completely with localization of insulin, indicating that
these MGO-AGEs-positive cells are b cells histologically
(Fig. 3D). We also observed that the co-localization of MGO-
AGEs and insulin was located within the cytoplasmic granule-
like structures in the b cells (higher magniﬁcation image of
merged picture in Fig. 3D). Double immunohistochemical
staining of MGO-AGEs and vesicle-associated membrane protein
2 (VAMP2), which is a marker protein of the vesicle membrane
including the insulin-secretory granules,20 indicated the co-
localization of both antigens in the pancreatic islets, except for
the islet periphery having the a cells (Fig. 3E). Co-localization of
insulin and VAMP2 were also observed in the same areas of
pancreatic islets (Fig. 3F). These results as a whole suggested the
existence of MGO-AGEs-modiﬁed proteins in the insulin-
secretory granules.
In pancreatic islets of the STZ-induced diabetic rats, the atrophic
morphological defects were observed, accompanying marked
decrease in the pancreatic b cells (Fig. 4B). These results are
Fig. 2. Speciﬁcity and cross-reactivity of anti-AGEs antibody against each of AGEs-BSA by using ELISA. The indicated AGEs-modiﬁed BSAs were coated on ELISA plate and subjected
to immunosorbent detection with anti-Glycer-AGEs antibody (A), anti-Glycol-AGEs antibody (B), anti-MGO-AGEs antibody (C) or anti-GO-AGEs antibody (D). Values represent the
means ± SE, measured with triplicate wells for each group. #P < 0.05, ##P < 0.01 compared with the Intact BSA group.
Table 1
Distribution of Glycer-AGEs in rat peripheral tissues.
Adipose Brain Colon Duodenum Eye Heart Kidney Lung Pancreas Spleen Stomach
Healthy  þ       þ  þ
Diabetic ND þ ND ND ND ND   þ ND ND
The indicated tissues were prepared from the healthy control rats or the STZ-induced diabetic rats and subjected to immunoﬂuorescent staining with anti-Glycer-AGEs
antibody (Alexa Fluor 488). þ: positive staining. : negative staining. ND: not determined.
Y. Morioka et al. / Journal of Pharmacological Sciences 134 (2017) 218e224 221attributed to the b cell-speciﬁc cytotoxicity, since STZ is a toxic
glucose analog which selectively accumulates in pancreatic b cells
through the GLUT2 glucose transporter. However, the remaining a
and b cells in the STZ-treated defective islets showed similar
localization pattern and immuno-intensity of Glycer- and MGO-
AGEs as compared with the healthy control rats, respectively
(Figs. 3A and 4).
4. Discussion
AGEs are one of the post-translational modiﬁcations involved in
various diseases, such as cancer,13 Alzheimer's disease,12 sarcope-
nia,21,22 arthritis,23 age-related macular degeneration (AMD),24
non-alcoholic steatohepatitis (NASH)25 and diabetes mellitus
(DM).3e5 Several antibodies against the speciﬁc AGEs subspecies
have been utilized to investigate the role of AGEs modiﬁcation.
However, these antibodies have different cross-reactivity against
each of AGE subspecies, because N-carboxymethyllysine (CML)-
protein adduct is a major immunological epitope in AGEs-modiﬁed
proteins.26 In addition, the major source of CML is vir lipid perox-
idation, not vir glycation.27 Therefore, it is necessary for the future
investigations to provide the more speciﬁc antibodies against the
AGEs structures associated directly with the AGEs-attributed
pathogenesis.In this study, we produced 4 kinds of polyclonal antibodies
against AGEs subspecies, glyceraldehyde-derived AGEs (Glycer-
AGEs), glycolaldehyde-derived AGEs (Glycol-AGEs), methylglyoxal-
derived AGEs (MGO-AGEs) and glyoxal-derived AGEs (GO-AGEs).
Conﬁrming the immuno-speciﬁcity of our antibodies by using the
immunochemical and histological analysis, we made use of these
antibodies to determine the localization of AGEs products in rat
peripheral tissues, especially focused on the histological localiza-
tion of Glycer-AGEs and MGO-AGEs in pancreatic islets.
The anti-Glycol-, MGO- and GO-AGEs antibodies showed clearly
the antigen speciﬁcities by using ELISA and immunoblot analysis,
whereas the anti-Glycer-AGEs antibody cross-reacted with both of
Glycer-AGEs and MGO-AGEs (Figs. 1 and 2). This cross-reactivity
may result from the immuno-afﬁnity of the anti-Glycer-AGEs
antibody against homologous structure between Glycer-AGEs and
MGO-AGEs. However, in immunohistochemical staining of rat
pancreas, the anti-Glycer-AGEs antibody showed the strong and
speciﬁc sensitivity, which was clearly different from other 3 kinds
of antibodies, the anti-Glycol-, MGO- and GO-AGEs antibodies
(Fig. 3A). Taken together, these results indicate that our antibodies
are available for immunohistochemical investigation.
AGEs are mainly generated under chronic hyperglycemic con-
ditions such as diabetes mellitus (DM) or age-associated diseases
such as Alzheimer's disease and atherosclerosis.5,12,28e30 The
Fig. 3. Immunohistochemical localization of Glycer-AGEs and MGO-AGEs in rat pancreatic islets. Pancreatic sections were prepared from the healthy control rats or the STZ-induced
diabetic rats and subjected to immunoﬂuorescent staining for AGEs subspecies. Representative images for the localization of AGEs subspecies in the pancreatic islets are shown. (A)
Control rabbit IgG and the indicated anti-AGEs antibodies against Glycer-AGEs, Glycol-AGEs, MGO-AGEs or GO-AGEs were used for the immunoﬂuorescent staining (Alexa Fluor
488). The upper and lower panels show the pancreas of the healthy control rats and the STZ-induced diabetic rats, respectively. (B) Double immunohistochemical staining with anti-
Glycer-AGEs antibody (Alexa Fluor 555) and anti-glucagon antibody (Alexa Fluor 488) is shown in the periphery of pancreatic islet derived from the healthy control rats. Arrowheads
indicate the double-positive cells. Arrow indicates Glycer-AGEs-positive but glucagon-negative cell. (C) Double immunohistochemical staining with anti-Glycer-AGEs antibody
(Alexa Fluor 488) and anti-insulin antibody (Alexa Fluor 555) is shown in the pancreatic islet derived from the healthy control rats. The right panel shows a magniﬁed image of
white square in the merged panel. (D) Double immunohistochemical staining with anti-MGO-AGEs antibody (Alexa Fluor 488) and anti-insulin antibody (Alexa Fluor 555) is shown
in the pancreatic islet derived from the healthy control rats. The right panel shows a magniﬁed image of white square in the merged panel. Arrowhead indicates the typical double-
positive cell. (E) Double immunohistochemical staining with anti-MGO-AGEs antibody (Alexa Fluor 488) and anti-VAMP2 antibody (Alexa Fluor 555) is shown in the pancreatic islet
derived from the healthy control rats. Arrowheads indicate the double-positive cells. Arrow indicates VAMP2-positive but MGO-AGEs-negative cell. (F) Double immunohisto-
chemical staining with anti-insulin antibody (Alexa Fluor 488) and anti-VAMP2 antibody (Alexa Fluor 555) is shown in the pancreatic islet derived from the healthy control rats. The
sections (BeF) were counterstained with DAPI. The scale bars indicate 100 mm (A) or 20 mm (BeF).
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Fig. 4. Immunohistochemical localization of Glycer-AGEs and MGO-AGEs in the pancreatic islets of STZ-induced diabetic rats. Pancreatic sections were prepared from the STZ-
induced diabetic rats and subjected to immunoﬂuorescent staining for AGEs subspecies. Representative images for the localization of AGEs subspecies in the pancreatic islets
are shown. (A) Double immunohistochemical staining with anti-Glycer-AGEs antibody (Alexa Fluor 555) and anti-glucagon antibody (Alexa Fluor 488) is shown in the atrophic islet
derived from the STZ-induced diabetic rats. Arrowhead indicates the double-positive cell. Arrow indicates Glycer-AGEs-positive but glucagon-negative cell. (B) Double immuno-
histochemical staining with anti-MGO-AGEs antibody (Alexa Fluor 555) and anti-insulin antibody (Alexa Fluor 488) is shown in the atrophic islet derived from the STZ-induced
diabetic rats. Arrowheads indicate the double-positive cells. The sections were counterstained with DAPI. The scale bars indicate 20 mm.
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to induce various inﬂammatory complications due to vascular
endothelial disorder.6
Takeuchi et al. have demonstrated that Glycer-AGEs have pre-
dominantly a toxic property among all AGEs subspecies,4,10,11,31
which is termed toxic AGEs (TAGE). TAGE is involved in the path-
ogenesis of vascular complications in DM patients. Moreover, the
ligand binding of TAGE through the receptor for AGEs (RAGE) alters
intracellular functions, such as gene expression, release of pro-
inﬂammatory molecules and production of reactive oxygen spe-
cies (ROS) in various peripheral tissues, all of which may contribute
to the pathological development observed in lifestyle-related
diseases.
On the other hand, the ﬁndings in this study show that the
Glycer-AGEs andMGO-AGEs were present in pancreatic islets of the
healthy control rats, which were clearly distinguished into two
types of islet cells, a cells and b cells (Fig. 3). Although the
remarkable decrease in the number of insulin-secreting b cells and
hyperglycemia were observed in STZ-induced rats, the localization
and deposit levels of Glycer- and MGO-AGEs appeared not to be
altered in the remaining a and b cells in the STZ-induced diabetic
rats (Fig. 4).
These results suggest that the cell-speciﬁc localization of AGEs-
modiﬁed proteins is related to healthy condition, involved in
physiological intracellular functions. In Fig. 3D and E, the MGO-
AGEs in pancreatic b cells were shown to be localized in the
insulin-secretory granules. MGO-speciﬁc glycation may serve a
critical role as post-translational modulation for the committed
proteins in the insulin secretion or maturation.32,33
Previous reports have shown that Glycer-AGEs treatment to rat
pancreatic b cells induces the cell injury by oxidative stress through
the mitochondrial pathway,34 and impairs glucose-induced insulin
secretion.35 These toxic effects are considered to result from the
extracellular stimuli of Glycer-AGEs through the ligand binding for
RAGE. As for an inﬂuence on cell function caused by intracellular
AGEs-deposit, little is known about the molecular mechanism
without the activation of RAGE signaling, at least in pancreatic
islets.
Glycation contributes to an inﬂuence on surface charge on
proteins leading to the structural and functional alterations, which
in turn affects a proteineprotein interaction and an afﬁnity forhydrophilic structures.36 Our present data suggests that the post-
translational modiﬁcations by speciﬁc AGEs subspecies have a po-
tential to inﬂuence on the physiological functions in the pancreatic
a and b cells.
In this study, we have provided the valuable antibodies against
speciﬁc AGEs subspecies for immunochemical detection in vivo and
suggested the presence of AGEs-speciﬁc physiological processes in
peripheral tissues. Further works are still required to understand
the critical differences between pathogenic and physiological AGEs
modiﬁcations in peripheral tissues through the lifespan.Conﬂict of interest
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